

Bayhill Therapeutics Appoints Fred Kurland as Chief Financial Officer

May 11, 2007

PALO ALTO, Calif. - (BUSINESS WIRE) - Bayhill Therapeutics Inc., a clinical-stage biotechnology company developing innovative therapies for autoimmune diseases, today announced that Fred Kurland joined the Company in the newly created position of Chief Financial Officer.

"We are delighted Fred has joined our management team," said Mark W. Schwartz, Ph.D., Bayhill Therapeutics' President and Chief Executive Officer. "Fred has an outstanding track record. He has led or been involved in numerous successful transactions during his 26 years in the pharmaceutical and biotechnology industries, including initial public offerings, acquisitions and divestitures, public and private financings and major collaborations. His experience will be key in managing Bayhill's future growth.

Fred Kurland was Chief Financial Officer of Corcept Therapeutics Incorporated from 2004 until April 2007. He served as Vice President and Chief Financial Officer of Genitope Corporation from 2002 until 2004. From 1998 to 2002 Mr. Kurland served as Senior Vice President and Chief Financial Officer of Aviron. He served as Vice President and Chief Financial Officer of Protein Design Labs, Inc. from 1996 to 1998 and from 1995 to 1996 he served as Vice President, Chief Financial Officer and Secretary of Applied Immune Sciences, Inc. Mr. Kurland held a number of financial management positions at Syntex Corporation between 1981 and 1995 including Vice President and Controller between 1991 and 1995. Mr. Kurland received his B.S. from Lehigh University and his J.D. and M.B.A. degrees from the University of Chicago.

About Bayhill Therapeutics

Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without affecting normal protective immune system cells. BHT-DNA is being studied in a recently completed Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic platform is an oligonucleotide; the first product candidate is in preclinical development for systemic lupus erythematosus.

More information about Bayhill Therapeutics is available at www.bayhilltx.com.

CONTACTS

Bayhill Therapeutics Inc.
650-320-2800

or

Burns McClellan, on behalf of Bayhill Therapeutics, Inc.

Susan Thomas

415-352-6262 (Media)

stthomas@burnsmc.com

John Cummings

415-352-6262 (Investors)

jcumings@burnsmc.com